Vatalanib succinate

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameVatalanib succinate
Drug Alias NameVatalanibum琥珀酸瓦他拉尼琥珀酸伐拉尼布伐他拉尼ZK-222584 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAromatase inhibitorsVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonists +[6] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[6] 
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursPrimary Myelofibrosis +[35] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteUniversity Of California San FranciscoWashington University School Of Medicine +[15] 
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorSolid tumoursPrimary Myelofibrosis +[35] 

Other Information

ATC CodeN/A
Related LinksDrugBank